Based on the earnings transcript, Amgen's stock price is likely to experience a positive impact in the short term (1â€“2 weeks). The company reported strong financial performance, with revenues and earnings per share increasing, and provided optimistic guidance for 2009. Additionally, the company's strategic initiatives, such as the launch of Denosumab and the potential for partnerships, suggest long-term growth potential. The management's confident tone and the company's strong balance sheet also contribute to a positive outlook.